Relationship between miRNAs dysregulation and the metastatic process associated with epithelial-mesenchymal transition in oral squamous cell carcinoma: A systematic review.

Arch Oral BiolJul 15, 2026 (epub)
Clinical ResearchOncology (Medical)

Flávia Letícia Magalhães Lemos, Lena Heloyse Dos Santos Guimarães, Nathalia Carolina Fernandes Fagundes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the link between miRNA dysregulation and the metastatic process related to epithelial-mesenchymal transition (EMT) in oral squamous cell carcinoma (OSCC). Eighteen studies were analyzed, revealing that eight deregulated miRNAs were significantly associated with lymph node metastasis, while four correlated with distant metastasis. The findings suggest potential diagnostic and therapeutic targets in OSCC management.

Key findings

  • Seventeen miRNAs involved in EMT regulation were identified, with five upregulated and twelve downregulated in OSCC tissues.
  • Eight deregulated miRNAs showed a significant association with lymph node metastasis.
  • Four miRNAs demonstrated a significant correlation with distant metastasis.

Why it matters

Understanding the role of miRNAs in the metastatic process of OSCC can enhance diagnostic accuracy and inform therapeutic strategies, potentially improving patient outcomes in clinical practice.

Source

PubMed · PMID 42480174

Published in Arch Oral Biol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.